Combinatorial Cancer Immunotherapies Review uri icon

Overview

MeSH Major

  • Cell Cycle Checkpoints
  • Costimulatory and Inhibitory T-Cell Receptors
  • Immunotherapy
  • Neoplasms
  • T-Lymphocytes
  • Tumor Microenvironment

abstract

  • © 2016 Elsevier Inc. T cell checkpoint blockade therapies are revolutionizing the treatment of patients with cancer. Highlighted by the recent success of PD-1 plus CTLA-4 blockade in patients with melanomas, synergistic immunotherapy combinations of modalities represent an important opportunity to improve responses and outcomes for patients. We review the rationale and experience with T cell checkpoint blockade in combination with targeting of other coinhibitory or costimulatory checkpoints, immunomodulatory molecules in the tumor microenvironment, and other anticancer modalities such as vaccines, chemotherapy, and radiation.

publication date

  • January 2015

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/bs.ai.2015.12.005

PubMed ID

  • 26923003

Additional Document Info